Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.85 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394085 | 1.00 | ELANE (0.85) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL394677 | 1.00 | ELANE (0.85) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL391816 | 0.92 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL395186 | 0.92 | ELANE (1.00) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL1245247 | 0.91 | ELANE (0.84) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL8347976 | 0.91 | ELANE (0.84) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL8347972 | 0.91 | ELANE (0.80) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL5107526 | 0.91 | ELANE (0.80) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL2679151 | 0.90 | ELANE (0.70) | ELANECYP2C9ADRB1HTR1AHRH3 | |
| SCHEMBL18204106 | 0.90 | ELANE (0.70) | ELANECYP2C9ADRB1HTR1AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009135599-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-12 | — | — | WO | disclosed |
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | ARGENTA DISCOVERY LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105268-A1 | Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors | SERPINB1, ELANE, MPO | ELANE 2/4885CYP2C9 3835/4885ADRB1 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.